Inclusion Criteria:  Patients with mild to moderate dementia in Alzheimer's disease, diagnosed using DSM-5 criteria. MMSE score from 12 to 26 points ADAS-Cog over 17 points Voluntary consent to participate in the study there is a related person or legal guardian who consented to assist the patient in the course of the study Minimum 8 years of education. It is allowed to use cholinesterase inhibitors and / or memantine for at least 3 months prior to study entry and at a stable dose for at least 60 days prior to study entry.  Exclusion Criteria:  Severe agitation Intellectual Disability Informed consent is not possible Unstable somatic condition Use of benzodiazepines or barbiturates 2 weeks prior to screening Participation in a clinical trial with coinciding factors within 6 months prior to the start of the trial Seizures Contraindications to rTMS treatment according to the rTMS questionnaire attached to the protocol Contraindications to tDCS treatment according to the tDCS questionnaire attached to the protocol Patients with depression, bipolar, or psychotic disorders, or any other neurological or psychiatric condition (current or past) that the Investigator considers to be interfering with the study Alcoholism or drug addiction as defined by DSM-5 in the last 5 years (addicted for more than a year and or in remission for less than 3 years) Patients with any medical condition that the Investigator considers to be an exclusion criterion from the study